Last reviewed · How we verify
AMB-05X
AMB-05X is a small molecule inhibitor of the PI3K delta subunit.
AMB-05X is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsing multiple sclerosis.
At a glance
| Generic name | AMB-05X |
|---|---|
| Sponsor | AmMax Bio, Inc. |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Biologic |
| Therapeutic area | Autoimmune diseases |
| Phase | Phase 2 |
Mechanism of action
AMB-05X works by selectively inhibiting the PI3K delta subunit, which is involved in the activation of immune cells. This inhibition leads to a reduction in the activity of these cells, resulting in a decrease in inflammation and potentially reducing the severity of autoimmune diseases.
Approved indications
- Relapsing multiple sclerosis
Common side effects
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment (PHASE2)
- A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT (PHASE2)
- An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee (PHASE2)
- A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients (PHASE2)
- A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |